Skip to main content

Table 2 The cumulative incidences of severity of hearing loss by type of aminoglycoside in the MDR-TB drug regimen

From: Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort

Severity of hearing loss Amikacin group (n = 51) Cumulative incidence Kanamycin group (n = 302) Cumulative incidence Total cases (N = 353) Cumulative incidence
Mild 5 10 % 60 20 % 65 18 %
Moderate 7 14 % 41 14 % 48 14 %
Moderate-Severe 6 12 % 27 9 % 33 9 %
Severe 5 10 % 16 5 % 21 6 %
Profound 11 22 % 21 7 % 32 9 %
Missing severity grading 4 8 % 3 1 % 7 2 %
Total cases 38 75 % 168 56 % 206 58 %